ArticleFrontiers in immunology2026
Mechanisms of therapeutic antibodies immunogenicity: infliximab oligomeric aggregates increase T-cell response and uptake by dendritic cells involving mannose-sensitive receptor CD206.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Aggregation of therapeutic antibodies (Ab)s is now recognized as a major product-related factor associated with increased potential of immunogenicity. Regulatory agencies have established limits for the presence of (sub)visible particles in commercialized products. These particles are considered a potential risk factor for the development of unwanted immune responses. However, little is known concerning the role of oligomeric Abs aggregates of nanometric size in Abs' immunogenicity. The objective of this work was to better understand the role and the mechanisms of T-cell response to nanometric Ab aggregates using infliximab (IFX) as a model. Method: We produced nanosized IFX aggregates by exposing native IFX to ultraviolet light. These aggregates were characterized using size exclusion chromatography (SEC), dynamic light scattering (DLS) and field flow fractionation coupled with a multi-angle light scattering detector (FFF-MALS). We then investigated the impact of IFX aggregation on its uptake by dendritic cells and the subsequent activation of IFX-specific T-cell responses. Results: Using a human in vitro autologous dendritic cell (DC)/T-cells coculture assay, we showed that aggregation increased the frequency of responsive T cells to IFX. Moreover, we observed exclusive T-cell responses to IFX aggregates and different TCR clonotypes responding to each form of IFX. Using fluorescent native or aggregated IFX, we found a significantly higher internalization rate of aggregated IFX by DCs in a mannose-dependent manner. Confocal microscopy experiments showed that aggregates were rapidly internalized and associated with markers of early endosomes and lysosomes as well as antigen presentation molecules, compared to the native form of IFX. Discussion: Our results suggest that internalization of IFX oligomeric aggregates via the mannose receptor pathway significantly contributes to enhanced IFX uptake by DCs and increased routing into the degradative pathway for processing into peptides. Increased presentation of immunogenic peptides may contribute to the augmentation of T-cell recruitment with aggregates compared to the native form. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.